• Tartisan Nickel Corp., a Canadian mineral and battery materials exploration and mining development company, recently announced a plan to complete an all-season access road at its flagship Kenbridge Nickel Project in Ontario
• This initiative will play a key role in improving the value of the property while also aligning with and providing benefit to Indigenous communities
• The move speaks to the company’s comprehensive and culturally sensitive approach to resource extraction, ultimately fostering a healthy relationship with the community

Tartisan Nickel (CSE: TN) (OTCQB: TTSRF) (FSE: 8TA), a Canadian mineral and battery materials exploration and mining development company, recently announced an ambitious plan to complete an all-season access road at its flagship Kenbridge Nickel Project in Ontario. As a critical initiative for the 2024 calendar year, its management noted its integral role in improving the property’s value, aligning with Indigenous communities.

“2024 promises to be a milestone year as multiple ongoing initiatives come together,” noted the company’s CEO, Mark Appleby. “Alignment with Indigenous communities, summation of baseline studies, project permitting endeavors, and all-season road access combined with continued efforts to expand the Kenbridge mine life are in focus and should prove to have a profound impact on shareholder value,” he added (https://ibn.fm/8EnR2).

To live up to its promise, Tartisan appointed Gregory (Greg) Edwards, B.Sc., Geo Eng., who would serve as Project Manager for the Kenbridge Nickel Project and the company’s First Nations Liaison. His appointment was informed by his consistent desire to work and foster good relationships with the three First Nations near the project. The move helped develop strong support from the surrounding indigenous community. To affirm that, in October 2021, the Kenbridge project received a blessing in a ceremony conducted by an elder from one of the First Nations, a tradition that it looks to maintain in all its projects going forward (https://ibn.fm/VqHNu).

Tartisan’s decisions and steps going forward are heavily informed by its surrounding community. As such, it looks to develop a more comprehensive and culturally sensitive approach to resource extraction by integrating traditional knowledge and leveraging Indigenous perspectives into their decision-making process. Adopting these steps, its management notes, will be integral in fostering a healthy and robust relationship with the community and extending the property’s life.

Its management maintains that 2024 will be a milestone year for the company. The additional claims acquisition earlier in May, its strategic appointments, and its partnerships so far in the year point to their confidence in the company’s direction and the potential of the flagship property. They also confirm its commitment to growing shareholder value while stamping Tartisan’s position as a leader in its space.

For more information, visit the company’s website at www.TartisanNickel.com.

NOTE TO INVESTORS: The latest news and updates relating to TTSRF are available in the company’s newsroom at https://ibn.fm/TTSRF

• Clene announced significant updates to their NIH-funded Accelerating Access to Critical Therapies Expanded Access Program (ACT-EAP) for CNM-Au8(R) compassionate use in amyotrophic lateral sclerosis (“ALS”)
• Clene has optimized its manufacturing, operational, and personnel processes to expand the program’s capacity to accommodate up to 180 participants
• The ACT-EAP, a collaboration among Clene, Columbia University, and Synapticure, was funded by the Accelerating Access to Critical Therapies for ALS Act (ACT for ALS), signed into law by Congress and President Biden in December 2021

Clene (NASDAQ: CLNN) and its subsidiary, Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company dedicated to improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases such as ALS and multiple sclerosis (“MS”), recently announced significant updates to their ACT-EAP for CNM-Au8 compassionate use in ALS (https://ibn.fm/aBWxl).

ALS is a fatal neurodegenerative disease with no known cure, making accessibility to treatment programs crucial. Recognizing this need, Clene has optimized its manufacturing, operational, and personnel processes to expand the program’s capacity to accommodate up to 180 participants.

In collaboration with Columbia University and Synapticure, Clene has secured a four-year grant totaling around $45m from the National Institute of Neurological Disorders and Stroke (“NINDS”), part of the NIH, to support an Expanded Access Program (“EAP”) for their investigational drug CNM-Au8 in ALS.

EAPs, also known as compassionate use programs, are FDA-regulated pathways that allow individuals with serious and life-threatening diseases to access investigational drugs not yet approved by the Food and Drug Administration. Funding for EAPs in ALS was strengthened by the ACT for ALS, signed into law by Congress and President Biden in December 2021.

Rob Etherington, CEO of Clene, said CNM-Au8 treatment has been associated with lowered risk of death and delayed clinical worsening, while being very well-tolerated in both of the company’s independent Phase 2 clinical studies. “Data from EAP programs, which usually include a broader ALS population than clinical trials, can supplement the safety and other meaningful data gathered from clinical studies,” Etherington added. “We are grateful for the NIH’s recognition to fund this important initiative and are pleased to provide this EAP for the ALS community. We are also grateful to the FDA for approving this EAP, working alongside Columbia University and Synapticure, to enable people who are living with this devastating disease access to our investigational drug CNM-Au8.”

Clene’s ACT-EAP is designed not only to meet FDA safety standards for EAPs but also to contribute valuable research data on ALS disease progression and therapy response. The program’s additional objectives include collecting real-world drug exposure data to enhance the CNM-Au8 clinical safety database and monitoring drug efficacy on survival and disease progression using natural history and control clinical trial database comparators. Biomarker data will also be collected and analyzed. This study is supported by the NIH under grant 1U01NS136023-01.

Dr. Jinsy A. Andrews, MD, MSc, FAAN, of Columbia University, and Principal Investigator on the grant, underscored that this was not just a standard EAP, in which Clene provides the investigational product to individuals with ALS through an FDA-regulated program. “A lot of time, careful thought, and effort have resulted in a study that will yield important insights into the real-world impact of CNM-Au8 treatment on the disease course of ALS,” Andrews explained.

The first patient visit for the ACT-EAP is scheduled for June 2024.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

• CEO Dr. Alan Baratz recently published a piece for the Forbes Technology Council that highlighted the transformation potential in bringing these two technologies together
• D-Wave is helping companies explore the powerful combination of quantum computing with AI to drive innovation, reduce carbon emissions, and solve complex problems

As artificial intelligence (“AI”) continues its rapid enterprise adoption trend, there is growing interest in how quantum computing can be used in conjunction with AI to create better, more cost- and energy-effective solutions in various fields, such as material science, logistics, and complex optimization problems. The way the two technologies could be used together is explored in a Forbes Technology Council column by D-Wave Quantum (NYSE: QBTS) CEO Dr. Alan Baratz (https://ibn.fm/kBjT6).

D-Wave, a pioneer in quantum computing, is developing annealing quantum computing technology specifically designed to address these challenges. In the Forbes column, Baratz explains that as AI continues to evolve, so will the computational resources and energy needs required to train and develop AI models. According to Dr. Baratz, quantum computing can successfully address some of these challenges by “helping businesses get more out of AI without being constrained by the limitations of classical computing.” This could enhance the applications of both technologies, including chemical simulations for drug discovery and financial modeling.

To implement quantum AI into their operations, Dr. Baratz believes that enterprises should start incorporating quantum technologies as soon as possible in order to maximize the impact of AI and to engage internal teams to identify where quantum AI can support their specific business challenges.

Innovative organizations may view quantum computing as a strategic advantage to outpace competitors. Quantum technology could offer significant business value, including finding supply chain efficiencies, reducing waste, shortening time to solutions, and tackling complex problems previously deemed unsolvable. Data from Hyperion Research indicates that 80% of early adopters of quantum technology plan to increase their investment in the next two to three years, with one-third intending to invest at least $15 million USD in quantum initiatives (https://ibn.fm/eUCsK).

D-Wave has achieved technological milestones that could push the boundaries of what is possible with quantum computing. Its focus on creating scalable quantum solutions positions the company as a key player in the field, driving the adoption of quantum technologies in practical applications. As the convergence of AI and quantum computing reshapes the technological landscape, Dr. Baratz believes that businesses must prepare for the disruptive potential of these advancements.

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward-Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of the company’s most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of the company’s Quarterly Reports on Form 10-Q and in its other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. The company undertakes no duty to update this information unless required by law.

The CWCBExpo is an essential B2B expo on the East Coast, being held at the Javits Convention Center in New York City. This year the Expo will be held from June 5-6, 2024, for two days of networking and engaging educational sessions.

The event schedule is meticulously planned as follows:

• June 4, 2024 – The exhibitors set up their booths, the pre-workshops are conducted on cultivation and operating a dispensary, and attendees can connect with industry colleagues at the rooftop bash that night.
• June 5, 2024 – After the registration and the media and press preview, the expo commences with a ribbon-cutting event. The expo floor opens and conference programs are conducted.
• June 6, 2024 – The attendees can participate in the conference programs and visit the expo on both the days. Along with business and networking, the participants can unwind, enjoy, and connect with industry influencers and peers at the luncheons, and after parties hosted by CWCBExpo on both the days.

Prominent members of the cannabis industry will share important insights, including:

• Industry icon Josh Kesselman, Founder and CEO, of HBI International / RAW Rolling Papers, who will preside over the fireside chat/keynote speaker session.
• Cy Scott, Co-Founder, CEO, of Headset, who will offer his insightful industry update on why New York is the next big cannabis market to watch out for and provide an update on rescheduling.

A special luncheon focusing on women in the cannabis business will be held on June 5, 2024. CWCBExpo is a leading B2B marketplace for networking within the cannabis community. Become a part of the interactive educational sessions, see unique product displays, participate in panel discussions, and seek the phenomenal opportunities offered by the CWCBExpo platform.

To learn more please visit https://ibn.fm/ZNIxm & https://ibn.fm/8lT47.

• ECGI Holdings is implementing an ongoing strategy to streamline its financials and improve its overall financial health, including the successful reduction of nearly $1.5 million in liabilities, a move seen as integral to its long-term strategy of continually improving its financial posture and overall economic vitality
• ECGI is also focused on exploring new pathways to monetize its underutilized assets, expanding its footprint within the luxury space with a specific focus on carving a niche in luxury branding and creating a luxurious short-term rental destination
• Looking ahead, ECGI will continue to focus on identifying and capitalizing on growth opportunities that align with its business objectives

ECGI Holdings (OTC: ECGI), a diversified holding company with a distinctive portfolio encompassing viticulture and luxury fashion, is implementing a broad strategy to streamline its financials and improve its overall financial health. This is part of the company’s financial optimization initiative aimed at strengthening its financial structure, cleaning up its balance sheet, reducing its liabilities, and boosting shareholder value.

The company has already successfully identified and carried out the reduction of nearly $1.5 million from its balance sheet. This reduction is hailed by the company as a testament to its commitment to operational efficiency and fiscal responsibility. By addressing and reducing its outstanding liabilities, ECGI said, “We are setting the stage for improved financial flexibility and the potential for future growth opportunities” (https://ibn.fm/Gyjbc). The company is committed to further identifying and reducing liabilities. This commitment underscores its strategic focus on “achieving a more robust and streamlined share structure, improving financial flexibility, and unlocking future growth opportunities.”

In addition to implementing its financial optimization initiative, ECGI is exploring new pathways to monetize its underutilized assets, including its captivating five-acre Petite Sirah vineyard in Lake County, California. Moreover, the company is expanding its footprint within the luxury space with a specific focus on building luxury brands.

To support this strategic focus, ECGI has invested in Pacific Saddlery, a premier manufacturer and retailer of luxury products and services synonymous with quality, elegance, and unrivaled value. Earlier this year, ECGI celebrated the launch of Pacific Saddlery’s new mobile retail boutique at the prestigious Desert International Horse Park’s Desert Circuit event held over ten weeks between January 10, 2024, and March 17, 2024 (https://ibn.fm/LB7JG).

In addition, through Evolve, a distinguished name in vacation rental management, ECGI is now transforming its 40-acre Lake County, California, property into a luxurious short-term rental destination named Vintner’s Caldera Ranch. The program was launched in early May (https://ibn.fm/OY1pQ), and includes exposure in Airbnb, Vrbo, and Bookings.com. Evolve will continue to leverage its expertise in maximizing rental potential and delivering exceptional guest experiences to ensure that Vintner’s Caldera Ranch exceeds the high standards of service and luxury that guests expect. According to the ECGI, this initiative is a testament to its innovative approach to realizing the value of its assets and marks a pivotal step toward diversifying and strengthening its portfolio.

For more information, visit the company’s website at www.ECGIHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to ECGI are available in the company’s newsroom at https://ibn.fm/ECGI

• HealthLynked is at the forefront of revolutionizing global healthcare related solutions for patients, doctors, and related healthcare organizations
• Some of the company’s solutions, including the HealthLynked Network, Augmented Real-Time Interface, and the new AI chat feature, incorporate artificial intelligence capabilities to foster better patient outcomes for all
• The new AI chat feature is designed to assist patients in locating healthcare providers across the country using markers such as name, specialty, or location and significantly enhance the effectiveness of the HealthLynked Concierge Team in reducing wait times and offering 24/7 service to users
• HealthLynked continues to lead in the development of advanced AI tools to meet the evolving needs of the healthcare sector

HealthLynked (OTCQB: HLYK) develops and deploys innovative healthcare solutions, serving patients, doctors, and support services, by leveraging advanced technology to provide more efficient, accessible, and personalized healthcare information whenever and wherever it is needed. One of these solutions is the HealthLynked Network, a sophisticated cloud-based platform and app designed to facilitate the seamless exchange of medical information between patients and healthcare providers.

According to the company, HealthLynked Network, partly powered by artificial intelligence (“AI”), is the only patient-centric medical network that allows users to store their medical information, book appointments with any doctor, access telemedicine services, chat with a nurse, receive assistance with medical forms and questions, co-manage family members’ healthcare, and obtain copies of their lab results among other services. The platform enables it to not only streamline the coordination of patient care, but also to analyze trends across large populations to manage health outcomes more proactively.

HealthLynked’s integration of AI capabilities into its sophisticated medical network builds on the company’s history of technological and A.I developments. In September 2021, it launched QwikCheck V2.0, a new check-in system using dynamic linking, which allows a single QR code tied to a practice that works seamlessly with both Android and iOS platforms. In October of 2023, HealthLynked filed a patent application for its Augmented Real-time Interface (“ARI”), which leverages the capabilities of AI to make healthcare more interactive, personalized, and user-friendly. According to the company, ARI is designed as a healthcare companion (virtual AI doctor) for patients, enabling them to interact with the HealthLynked Network. It utilizes advanced NLP technology, allowing patients to converse directly with the system. By using ARI, patients can ensure that their medical records are current, and eventually provide them customized guidance to address their specific healthcare requirements.

As part of its A.I. integration, HealthLynked recently announced the launch of a new AI-powered chat function, which integrates AI into the company’s concierge service. The chat function is designed to assist patients in locating any of the 800,000 healthcare providers across the country stored in HealthLynked’s extensive database using identifiers such as name, specialty, or location. It is also designed to provide instant answers to customer questions, helping reduce wait times and offering 24/7 service for its users. If the AI is unable to answer a query, the chat will be seamlessly transferred to a live representative. HealthLynked expects this advanced feature to significantly enhance the effectiveness of its Concierge Team, which is responsible for engaging patients (https://ibn.fm/vQ7YE).

Following the launch, the company has embarked on integrating its comprehensive healthcare provider database with the new AI system, with this integration expected to be completed over the next few months. Once fully operational, this technology is anticipated to streamline the company’s operations, reduce wait times, and enhance the overall user experience.  This integration is expected to result in higher demand for the HealthLynked app as it would be the only A.I. – enhanced comprehensive healthcare app in the marketplace.

“Our new AI chat function is a testament to our commitment to leveraging cutting-edge technology to improve healthcare accessibility. By integrating AI into our platform, we can provide more efficient and timely support to our users, ensuring they receive the care they need without unnecessary delays,” commented Dr. Michael Dent, CEO of HealthLynked.

Further, according to Chris Hall, CTO of HealthLynked, the company is excited to continue developing and deploying advanced AI tools to meet the evolving needs of its users. As the company continues to expand its AI capabilities, HealthLynked expects to deliver more effective, timely, and cost-effective solutions to patients and users seeking answers to healthcare queries.

For more information, visit the company’s website at www.HealthLynked.com.

NOTE TO INVESTORS: The latest news and updates relating to HLYK are available in the company’s newsroom at https://ibn.fm/HLYK

• Emperor Metals announced an ambitious initial 2024 fully funded 8,000-meter drill program and 8,000-meter historical core assaying at its Duquesne West Gold Project, set to commence this month
• Emperor is fully funded with approximately $4 million in working capital and will advance the Duquesne West project towards an updated mineral resource expected by Q1, 2025
• Company receives $1 Million From Industry Legend – Rob McEwen, Founder of Goldcorp

Emperor Metals (CSE: AUOZ) (OTCQB: EMAUF) (FRA: 9NH), an advanced stage gold exploration company focused on proving and developing the substantial resource potential of its flagship Duquesne West Gold Project located in the Tier 1 district of the Southern Abitibi Greenstone belt of Rouyn-Noranda, Quebec, recently announced that it is continuing to strengthen its position in gold exploration through recent advancements. These efforts show the company’s commitment to expanding its resource base and enhancing shareholder value.

The company has also announced an ambitious 8,000-meter drill program and 8,000-meter of historical core assaying at its Duquesne West Gold Project. This extensive drilling program is designed to expand the current resource base and explore new zones of mineralization within the project area. This strategic move not only aims to enhance Emperor’s asset portfolio but also demonstrates the company’s proactive approach to resource development.

In 2023, Emperor Metals conducted a successful drilling campaign at Duquesne West, achieving high-grade intercepts and identifying potential for a conceptual open-pit mining scenario. This approach could significantly improve the project’s economics by reducing stripping ratios and increasing recoverable ounces. Emperor Metals plans to continue this momentum with a fully funded Phase II drilling program, set to commence in May 2024. This program aims to further delineate resources and enhance the open-pit model.

Emperor Metals CEO John Florek, said the company was excited to resume drilling at Duquesne West Gold Project and continue its success in 2024 after a transformative year in 2023 with the revelation of a significant open pit concept above a high-grade gold deposit. “This gives Emperor the ability to add ounces more rapidly on this project due to the capability of adding potentially open pitable mineralization above the high-grade historical resource. Emperor is well funded with approximately $4 million in working capital and will advance the Duquesne West project towards an updated mineral resource,” Florek added (https://ibn.fm/Dk5Rc). “Gold prices continue to show strength, and we are confident that everything is now in place to give our shareholders the best chance of a successful upside on this project.”

The company is committed to updating the historical mineral resource estimate to comply with modern standards by Q1 2025. The company’s long-term objectives include advancing the project toward a Preliminary Economic Assessment (“PEA”) or more advanced studies. With a dedicated team of experienced professionals, Emperor Metals is well-equipped to navigate the complexities of gold exploration and development, ensuring sustained growth and value creation for its stakeholders.

These recent developments showcase Emperor Metals’ strategic vision and operational capabilities. By resuming drilling at Duquesne West, and securing significant financial investment, Emperor Metals is well-positioned to advance its exploration project and deliver value to its stakeholders. As the company progresses with its initiatives, it continues to reinforce its standing as a dynamic player in the gold exploration industry.

A strong show of faith in the company’s project is the $1 million investment made by industry legend Robert McEwen, CEO of McEwen Mining Inc., mentioned in a recent interview with Emperor Metals CEO John Florek (https://ibn.fm/022i4).

For more information, visit the company’s website at www.EmperorMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to EMAUF are available in the company’s newsroom at https://ibn.fm/EMAUF

• Company calls rescheduling a “monumental decision” that signifies a significant shift in U.S. drug policy
• MedCana CEO notes rescheduling “opens the door to further research, innovation and accessibility, signaling a new era of acceptance and understanding”
• SFWJ remains committed to advancing the dialogue around cannabis policy and supporting initiatives that promote responsible access and use

Software Effective Solutions (d/b/a MedCana) (OTC: SFWJ) has noted a “historic milestone” as the U.S. Drug Enforcement Administration (“DEA”) moves to reclassify cannabis from Schedule I to Schedule III under the Controlled Substances Act (https://ibn.fm/7GASG). The company released an announcement from CEO Jose Gabriel Diaz and observed that the “monumental decision,” based on recommendations from the U.S. Department of Health and Human Services, signifies a significant shift in U.S. drug policy.

“The DEA’s decision to reclassify cannabis is a watershed moment in our nation’s drug policy,” said Diaz. “It opens the door to further research, innovation and accessibility, signaling a new era of acceptance and understanding. MedCana is proud to be part of an industry that advocates for sensible cannabis regulation and equitable access to this vital medicine.”

MedCana joined many companies in responding to the proposed reclassification. “Many applauded the move to Schedule III from Schedule I, which the Associated Press first reported and was later confirmed by a Department of Justice spokesperson in a statement to Cannabis Business Times,” reported the Cannabis Business Times (https://ibn.fm/9JfYW). “Executives from plant-touching companies noted its significance as a historic step toward federal cannabis reform, destigmatization, fairer tax policies for businesses and more research into cannabis’s medical benefits.

“However, many also tempered the celebratory tone and said that there was much more work to be done,” the article continued. “Leaders from industry nonprofit organizations and some lawmakers emphasized their call for the federal government to deschedule cannabis altogether, something they urged after news circulated that the U.S. Department of Health and Human Services (‘HHS’) recommended that the DEA reschedule cannabis in August 2023.”

While there may be work left to do, the initial rescheduling is certainly noteworthy. The announcement from MedCana noted that cannabis has been unjustly categorized as a Schedule I substance alongside heroin and LSD for more than four decades. This was despite the fact that the substance has recognized medical benefits and low potential for abuse. The DEA’s move to reschedule cannabis — a move that will now undergo a period of public comment — is a clear indication of its therapeutic value and aligns with evolving attitudes toward cannabis policy.

In its announcement, MedCana stated that it remains committed to advancing the dialogue around cannabis policy and supporting initiatives that promote responsible use and access to quality cannabis products.

Operating under Software Effective Solutions Corp., MedCana is a pioneer in the integration of technology and agriculture, focusing on the cannabis market and emerging technologies in agriculture. With a vision to revolutionize the industry through innovation, MedCana is dedicated to acquiring and partnering with companies that align with its mission of promoting sustainable and technologically advanced agricultural practices.

For more information, visit the company’s website at www.MedCana.net.

NOTE TO INVESTORS: The latest news and updates relating to SFWJ are available in the company’s newsroom at https://ibn.fm/SFWJ

Entrepreneurs, traders, enthusiasts, patients, consumers, and service providers of the cannabis industry are invited to attend the Vermont Cannabis & Hemp Convention, a pioneering B2B cannabis industry event on the East Coast. Engaged in organizing conventions since 2014, NECANN believes in bringing together the local cannabis community for better growth and business prospects. The event features the expo, workshops, and programming tracks, in addition to speaker sessions and panel discussions by industry experts. The age limit to attend the conference is 21+.

The NECANN team comprises a group of passionate and talented professionals who design an extensive agenda that involves two days of robust learning, exploration, and networking. The attendees can connect with investors and peers for collaborations and a higher ROI. New businesses as well as seasoned traders exhibit their innovative products and services to leverage the expensive reach of the NECANN platform.

Investors and businesses looking for fresh areas of investment can discover new and exciting products at the exhibition booths. NECANN is a profitable forum for the local community of cultivators, growers, traders, and businesses in Vermont and New England vicinity. The networking connections developed at the NECANN convention will help local retailers expand their reach to earn new businesses and customers.

The convention will feature an impressive line of industry leaders who preside over the speaker sessions at the summit. They will offer their priced insights and strategies on the latest trends in the market. The experts will also talk about the role of AI in shaping consumer experience, the latest regulations, and several other topics of importance. Attendees can customize their schedule and only their bookmarked events.

To know more, please visit https://ibn.fm/yft0X.

• Completion of a 70,000 meters drilling program at Los Azules project, is confirming the potential for significant copper production
• Discovery of significant mineralization extensions beyond the planned pit area, suggesting the possibility of resource expansion
• Strategic multi-year drilling campaign aimed at supporting the Los Azules Bankable Feasibility Study, with a focus on sustainability and low environmental impact

McEwen Copper Inc., under the partial ownership of McEwen Mining (NYSE: MUX) (TSX: MUX), has made significant progress at its Los Azules project in Argentina, marking a pivotal moment with the recent completion of a comprehensive 70,000 meters drilling program. This achievement is not just a technical milestone but also a testament to the company’s commitment to advancing the project towards production. The impressive assay results, including sections with high copper grades, underscore the potential of Los Azules to become a significant producer of green copper.

The drilling campaign was meticulously designed to achieve several critical objectives, crucial for the project’s development. By confirming the size and grade of the deposit, McEwen Copper aims to solidify its understanding of Los Azules’ potential compared to initial estimates.

Furthermore, the discovery of significant mineralization extensions beyond the planned pit area, both to the north and south, opens new avenues for resource expansion. This, coupled with the identification of a new porphyry system east of the main deposit, suggests that Los Azules could exceed current expectations in terms of size and mineral wealth. Such findings could potentially enhance the project’s economics and extend its life.

The ongoing 2023-2024 drilling campaign is a strategic effort to gather all necessary data for the Los Azules Feasibility Study, expected to be completed by early 2025. By focusing on converting resources to higher confidence categories and conducting various supportive studies, McEwen Copper is laying a solid foundation for the project’s future development. This meticulous approach is aimed at ensuring the project’s viability and profitability, particularly during the critical initial payback period.

McEwen Copper’s vision for the Los Azules project, emphasizing sustainability and low environmental impact, aligns with the growing demand for responsible mining practices. The project’s design to utilize renewable energy and minimize water and carbon footprints sets a precedent in the industry. Coupled with the updated PEA’s promising projections, including a high after-tax IRR, Los Azules stands out as a potentially transformative project for McEwen Mining, promising to bolster its portfolio and contribute significantly to its growth strategy in the copper sector.

For more information, visit the company’s website at www.McEwenMining.com.

NOTE TO INVESTORS: The latest news and updates relating to MUX are available in the company’s newsroom at http://ibn.fm/MUX